


1 image

1654


CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No. NOV-0001	
Applicant(s): Sophie Chen				
Serial No. 10/072,8523	Filing Date February 8, 2002	Examiner Michael V. Meller	Group Art Unit 1654	
Invention: ANTI-CANCER AGENTS AND METHOD OF USE THEREOF				
				
I hereby certify that this <u>IDS (1 pg); Trans. of IDS (2 pgs); Inf. Disc. Cit. (8 pgs) & 57 references</u> (Identify type of correspondence)				
is being deposited with the United States Postal Service as first class mail in an envelope addressed to:				
Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450				
on <u>April 9, 2004</u> (Date)				
<u>Lindsay Wells</u> (Typed or Printed Name of Person Mailing Correspondence)				
<u>Lindsay Wells</u> (Signature of Person Mailing Correspondence)				
Note: Each paper must have its own certificate of mailing.				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. NOV-0001
In Re Application Of: SophieChen			
Serial No. 10/072,823	Filing Date February 8, 2002	Examiner Michael V. Meller	Group Art Unit 1654
Title: ANTI-CANCER AGENTS AND METHOD OF USE THEREOF			
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
37 CFR 1.97(b)			
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
37 CFR 1.97(c)			
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);			
OR			
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NOV-0001

In Re Application: SophieChen



Serial No.

10/072,823

Filing Date

February 8, 2002

Examiner

Michael V. Meller

Group Art Unit

1654

ANTI-CANCER AGENTS AND METHOD OF USE THEREOF

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **06-1130** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 9, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lindsay Wells
Signature of Person Mailing Correspondence

Lindsay Wells

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Karen A. LeCuyer
Signature

Dated: April 8, 2004

Karen A. LeCuyer Ph.D.

Registration No. 51,928

Customer No. 23413

Cantor Colburn LLP

55 Griffin Road South

Bloomfield, CT 06002

(860) 286-2929

CC:



NOV-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sophie Chen)
Serial No.: 10/072,823) Group Art Unit: 1654
Filing Date: February 8, 2002) Examiner:
For: ANTI-CANCER AGENTS AND) Michael V. Meller
METHODS OF USE THEREOF)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: Karen A. LeCuyer
Karen A. LeCuyer Ph.D.
Registration No. 51,928

Date: April 8, 2004
Customer No. 23,413
(860) 286-2929



SERIAL NO. 10/072,823

FILING
February 8, 2002


GROUP	1654
-------	------

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


DATE CONSIDERED



SERIAL NO. 10/072.823

FILING
February 8, 2002

GROUP	1654
-------	------



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO. NOV-0001	SERIAL NO. 10/072,823
Sophie Chen	
FILING February 8, 2002	GROUP 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
31	✓	WO 01/21009 A2	3/29/2001	PCT			✓	
32	✓	EP 1 029 545 A2	8/23/2000	EUROPE				✓
33	✓	GB 2 346 325 A	8/9/2000	GREAT BRITAIN			✓	
34	✓	EP 0 633 022 A	1/11/1995	EUROPE			✓	
35	✓	EP 1 127 572 A	8/29/2001	EUROPE			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

36	✓	Naohito, et al; "Resistance of Highly Branched (1 fwdarw 3) - beta-D-glucans to Formolysis"; CHEMICAL AND PHARMACEUTICAL BULLETIN (TOKYO); Vol. 43, No. 6; 1995, Abstract Only; XP 002268301
37	✓	Hamuro et al; "Solid Phase Activation of Alternate Pathway of Complement by Beta-1 3 Glucons and its Possible Role for Tumor Regressing Activity"; IMMUNOLOGY, Vol. 34, No. 4; 1978; Abstract Only; XP 002268302

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>		Docket Number (Optional) NOV-0001		Application Number 10/072,823	
		Applicant(s) Sophie Chen			
		Filing Date February 8, 2002		Group Art Unit 1654	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
45	✓	JP 09301915, Abstract Only, 25-11-97, 1 page			
46	✓	Dae Sik Jang et al, "Prenylated Flavonoids of the Leaves of Macaranga Conifera with Inhibitory Activity Against Cyclooxygenase-2", PHYTOCHEMISTRY, Vol. 61, 2002, pages 867-872			
47		International Search Report, International Application No. PCT/US 03/06979, International Filing Date 06/03/2002, Date of Mailing 01/03/2004			
48		International Search Report, International Application No. PCT/US 03/24088, International Filing Date 01/08/2003, Date of Mailing 05/03/2004			
49	✓	JP 60178815, Abstract Only, 1986-01-29, XP002268305 1 page			
50	✓	JP 06024975, Abstract Only, 1994-02-01, XP002268306, 1 page			
51	✓	JP 61263925, Abstract Only, 1986-11-21, XP 002268307, 1 page			
52	✓	JP 08104628, Abstract Only, 1996-04-23. XP 002268308, 2 pages			
53	✓	JP 2000 239136, Abstract Only, 2000-09-05, XP 002268309, 2 pages			
54	✓	JP 04283518, Abstract Only, 1992-10-08, XP 002268310, 1 page			
55	✓	JP 2001 114675, Abstract Only, 2001-05-24, XP 002268311, 4 pages			
56	✓	JP 52 145509, Abstract Only, 1977-12-03, XP 002268312, 1 page			
EXAMINER			DATE CONSIDERED		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

